Close Menu
Invest Insider News
    Facebook X (Twitter) Instagram
    Sunday, November 22
    Facebook X (Twitter) Instagram Pinterest Vimeo
    Invest Insider News
    • Home
    • Bitcoin
    • Commodities
    • Finance
    • Investing
    • Property
    • Stock Market
    • Utilities
    Invest Insider News
    Home»Finance»Poolbeg Pharma Is Just One Of 3 British Healthcare AI Stocks
    Finance

    Poolbeg Pharma Is Just One Of 3 British Healthcare AI Stocks

    November 22, 20265 Mins Read


    The global AI boom is putting fresh pressure on electricity grids, and that matters for healthcare. British hospitals, clinics and drug researchers need reliable computing power to train medical algorithms and run data heavy tools, yet power costs and supply constraints keep biting. Investors looking at UK healthcare AI stocks are watching this closely, and this article highlights three screened companies aiming to tackle medicine with smarter software.

    The three UK stocks below are just a small sample of the idea, and the wider screen surfaced 6 more healthcare AI companies with equally compelling stories that are not covered here.

    If you want to identify potential leaders and analyze how different medical AI plays stack up, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener

    Poolbeg Pharma is a London based clinical stage biopharma group developing POLB 001 for cancer immunotherapy related cytokine release syndrome and influenza, oral GLP 1 obesity and diabetes candidates, plus an in house AI drug discovery program targeting influenza and RSV, with a market value of about £47 million.

    Poolbeg Pharma provides focused exposure to AI driven drug discovery in infectious disease, backed by a growing IP estate around POLB 001 and an active CRS clinical trial program. It remains loss making with minimal revenue, so its long term appeal depends on how one crucial funding and data inflection develops.

    That hinges on what the next round of data and cashflow looks like, so it is worth lining that up against the 2 warning signs (1 is major!) before forming a view.

    AIM:POLB 1-Year Stock Price Chart
    AIM:POLB 1-Year Stock Price Chart

    IXICO runs AI-enabled neuroimaging services that help drug developers and clinicians read brain scans for Alzheimer’s, Parkinson’s and other neurological diseases, using its IXICO platform and imaging CRO tools. It reported £7.3 million of Medical Labs & Research revenue and carries a market value of about £28.5 million.

    IXICO plugs AI directly into MRI and PET brain imaging so pharma clients can detect disease signals faster, manage trials more efficiently and support clinical decisions in disorders where every data point is precious. The opportunity is clear, although profitability and funding still hinge on how one unseen pressure shapes future pricing power and contract depth.

    That hidden pressure is already reshaping the risk reward, so line IXICO up against the 1 key reward and 4 important warning signs (2 are major!) to see what might accelerate or stall its momentum.

    AIM:IXI Earnings & Revenue History as at Nov 2026
    AIM:IXI Earnings & Revenue History as at Nov 2026

    EMV Capital is a London based venture investor backing early and mid stage AI, digital health and diagnostics startups that use data analytics, wearables and software to manage chronic disease and personalise care, with a market value of about £12.6 million.

    EMV Capital provides indirect exposure to AI powered healthcare tools through a portfolio of digital health and diagnostics holdings. This portfolio has recently swung to profitability on £1.27 million of half year sales and reported £18.14 million of net income. Future returns depend on how one crucial set of exits and revaluations unfolds.

    Those exit and revaluation swings are already in motion, so size up EMV Capital against the 3 key rewards and 2 important warning signs (1 is major!) before those portfolio moves fully reprice expectations

    AIM:EMVC Earnings & Revenue History as at Nov 2026
    AIM:EMVC Earnings & Revenue History as at Nov 2026

    Curious About Alternative Opportunities?

    Fresh ideas move first. Potential breakouts can gain momentum while slow capital gets caught watching from the sidelines. Scan new themes that may be under the radar for now and consider them promptly.

    • Spot cash generative outliers early and track a curated 18 high quality undervalued stocks before valuations move away and the most attractive entry points start dropping out of reach.

    • Hunt for resilient compounders by scanning a focused list of solid balance sheet and fundamentals (7 results) where stronger finances support staying power while it can still be beneficial to be early.

    • Zero in on fast growing AI operators using a filtered 4 AI small caps to follow recent momentum stories before broader attention potentially changes how they are priced.

    This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleMainstream media has avoided Bitcoin energy myths for over a year, Daniel Batten notes
    Next Article Asian countries take steps to aid stock markets after AI rout

    Related Posts

    Finance

    What Nemetschek Bears Saw Before The Fall

    November 22, 2026
    Finance

    Best corporate finance advisers in the UK for founders planning life after exit

    November 22, 2026
    Finance

    Why women founders still struggle to find finance that fits | The Social Enterprise Magazine

    November 22, 2026
    Leave A Reply Cancel Reply

    Top Posts

    How is the UK Commercial Property Market Performing?

    December 31, 2000

    How much are they in different states across the US?

    December 31, 2000

    A Guide To Becoming A Property Developer

    December 31, 2000
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews
    Bitcoin

    Bitcoin Cash rises on retail interest and $600 breakout focus

    December 18, 2025
    Finance

    Finance Committee to look at $136K contract for alcohol, drug detoxification services

    October 29, 2024
    Investing

    Asia stocks erase early gains as oil surge weighs; Alphabet results ahead By Investing.com

    July 21, 2026
    What's Hot

    Davis Commodities Evaluates Strategic Solana Reserve to Support ESG-Linked Digital Initiatives

    July 11, 2025

    Former Fed Chair Jerome Powell Did Something That’s Only Been Done Once Before in 30 Years, and It May Continue to Send Shockwaves Through the Stock Market.

    May 31, 2026

    U.S.-Iran War: Iran Claims Tanker Attacks as War Pushes Brent Crude Past $90, Bitcoin Falling

    July 20, 2026
    Most Popular

    Human remains found on property of man whose wife disappeared

    August 19, 2024

    UK property listings rise 7% as supply outpaces demand

    February 5, 2026

    Bitcoin Price Prediction As US House Passes Government Funding Bill to End Shutdown

    February 4, 2026
    Editor's Picks

    Here’s What Pete Hegseth Just Said About Bitcoin and Why It Matters

    May 6, 2026

    Car finance compensation: Your ultimate guide to how payouts will work

    April 3, 2026

    ‘Stock Market Has Been The Best Place To Be, But If You Need Money In 1 or 2 Years, You Shouldn’t Be Buying Stocks’

    August 17, 2025
    Facebook X (Twitter) Instagram Pinterest Vimeo
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions
    © 2026 Invest Insider News

    Type above and press Enter to search. Press Esc to cancel.